ATS Corporation reports Q1 adjusted EPS 50c vs. 50c last year

Reports Q1 revenue $694.3M vs. $753.6M last year. “Today ATS reported our first quarter results for fiscal 2025, which included the second highest Order Bookings and the largest life sciences Order Backlog in company history,” said CEO Andrew Hider. “Strengthened by organic and acquisition growth within life sciences, our Order Backlog provides good revenue visibility throughout FY25. In transportation, we are taking action to align our cost structure to a lower demand environment, with the expectation that Order Bookings in the Electric Vehicle space will be a smaller part of our portfolio going forward. As we drive our strategic focus on expanding our presence in regulated markets such as food and beverage and life sciences, our recent acquisitions, including Avidity, as well as Paxiom, which we recently welcomed to the ATS portfolio, create opportunities for both organic and synergistic growth with accretive margin profiles.”